Antiphospholipid Antibodies and Early Severe Preeclampsia.
|ClinicalTrials.gov Identifier: NCT01538121|
Recruitment Status : Unknown
Verified January 2015 by Osvaldo A. Reyes T., Saint Thomas Hospital, Panama.
Recruitment status was: Not yet recruiting
First Posted : February 23, 2012
Last Update Posted : January 5, 2015
|Condition or disease|
|Severe Preeclampsia Antiphospholipid Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||310 participants|
|Observational Model:||Case Control|
|Official Title:||Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.|
|Study Start Date :||June 2015|
|Estimated Primary Completion Date :||July 2016|
|Estimated Study Completion Date :||August 2016|
Cases-Early Severe Preeclampsia
Patients with severe preeclampsia before 34 weeks of gestation
Patients with normal pregnancies at term.
- Lupus anticoagulant [ Time Frame: 15 months ]Number of cases positive for Lupus Anticoagulant.
- Anticardiolipin antibodies [ Time Frame: 15 months ]Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.
- B2 Glycoprotein I [ Time Frame: 15 months ]Number of cases with levels of B2 Glycoprotein 1 > 99%
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538121
|Saint Thomas Maternity Hospital|
|Principal Investigator:||Osvaldo A Reyes, MD||Saint Thomas Hospital, Panama|